Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus
ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.
Pharma & Biotech
Pharma & Biotech
Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications
FDA approves Teva’s DEGEVMA as an Xgeva biosimilar across oncology bone-disease indications, expanding its U.S. denosumab portfolio.
Pharma & Biotech
One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal
Five-year CARTITUDE-2 data show 50% of 20 early-line relapsed multiple myeloma patients remained alive and progression-free after a single Carvykti infusion without maintenance therapy, strengthening the case for using CAR-T before heavily pretreated disease.
Pharma & Biotech
MediciNova stock up 85% in September as pivotal ALS trial reaches final patient visit
MediciNova has completed the final patient visit in the blinded portion of its 234-patient COMBAT-ALS study, starting the countdown to pivotal MN-166 results expected by year-end as MNOV shares emerge as one of September’s strongest-performing healthcare stocks.
Pharma & Biotech
Merck KGaA’s $11.3bn Bio-Techne deal clears shareholder vote as life-science tools consolidation advances
Bio-Techne shareholders have approved Merck KGaA’s $11.3 billion cash acquisition, clearing a major hurdle in a transaction designed to expand the German group across multi-omics, spatial biology, precision diagnostics and cell therapy workflows.
Pharma & Biotech
FDA sets January decision for Pharming Group’s lower-dose Joenja pediatric expansion
FDA grants Priority Review to lower-dose Joenja for children with APDS weighing 13–27 kg, setting a January 30, 2027 decision date.
Pharma & Biotech
Five-year CARVYKTI data deepen evidence for durable remission in earlier-line multiple myeloma
CARVYKTI keeps half of CARTITUDE-2 patients progression-free and treatment-free at five years after one infusion. See what the data mean.
Pharma & Biotech
Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?
Eli Lilly and Company has secured U.S. Food and Drug Administration approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, bringing a second weekly insulin into the U.S. market and shifting the competitive question from regulatory feasibility to prescribing, access and real-world adoption.
Pharma & Biotech
Prime Medicine stock jumps after FDA clears PM647 gene-editing trial for alpha-1 antitrypsin deficiency
Prime Medicine shares jumped in after-hours trading after the FDA cleared PM647 for first-in-human testing, moving a one-time gene-editing therapy for alpha-1 antitrypsin deficiency from promising animal data into the much harder test of clinical development.
Pharma & Biotech
Merck’s $3bn EyeBio bet clears first pivotal test as remigromig matches Lucentis
Merck & Co.’s remigromig matched ranibizumab on vision improvement in a pivotal diabetic macular edema trial, validating a novel Wnt-targeting approach while higher rates of proliferative diabetic retinopathy and vitreous hemorrhage leave an important safety question unresolved.